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Introduction
Knowledge of prognostic factors is essential for oncol-
ogy practice because it helps physicians in consulting
patients and to select appropriate treatment for indi-
vidual patients.1 For prostate adenocarcinoma, some of
the prognostic factors have been well established, such
as initial serum prostate specific antigen (PSA), Gleason
score and pathologic stage.2 However, all of these fac-
tors are hard to apply to the individual patient. With
recent developments in molecular biology, we may now
be able to identify new marker(s) for predicting clinical
outcome of cancer patients.
Cyclins and cyclin-dependent kinases (CDK) are
necessary for the induction of DNA replication.3
p21WAF1 is an inhibitor of CDK, and appears to 
be activated by wild-type p53 protein.4,5 Through
both p53-dependent and p53-independent pathways,
p21WAF1 blocks cell cycle progression at the G1 phase.5–9
p21WAF1 expression has been found to be correlated
with advanced stage, higher Gleason score and short-
ened biochemical-free survival in prostate cancer,
although the exact mechanism remains unknown.10–13
In 1 study, expression of p21WAF1 was identified as a
poor prognostic marker for Caucasian but not African-
American prostate cancer patients.11 Since the p21WAF1
gene is regulated transcriptionally by p53,5,11 and 
our previous study illustrated that p53 mutation was
less common and without prognostic significance in
Taiwanese prostate cancers,14 it would be interesting
to further examine the expression of p21 in Taiwanese
prostate cancer patients.
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(pT2) prostate cancer patients.
Methods: The medical records of 53 pT2 prostate adenocarcinomas were analyzed retrospectively. Radical prostatec-
tomy specimens were stained using anti-p21WAF1 and anti-p27KIP1 antibodies. Biochemical relapse was defined as 2 con-
secutive elevations in serum prostate specific antigen (PSA) level > 0.2 ng/mL with an interval of more than 3 months.
The prognostic significance of p21WAF1 and p27KIP1 expression was assessed.
Results: p21WAF1 immunoreactivity was found in 19 patients (35.8%). Twenty-nine tumors (54.7%) had decreased
p27KIP1 expression. Both markers were not associated with Gleason scores (p = 1.00 for both). At a median follow-up of
49 months, 15 patients (28.3%) experienced biochemical recurrence. Both p21 and p27 had no prognostic significance
in log-rank test (p = 0.98 and p = 0.64, respectively). 
Conclusion: p21WAF1 and p27KIP1 expression have no role in predicting biochemical relapse for stage pT2 prostate cancers.
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Cell proliferation is inhibited by p27KIP1 by bind-
ing and inactivating the cyclin-CDK complex, thereby
blocking the transition from G-1 to S-phase.3,15–17
Decreased p27KIP1 expression has recently been asso-
ciated with high grade tumor and poor clinical out-
comes in prostate cancers. However, the data are
inconsistent.16–21
This study focused on the significance of p21WAF1
and p27KIP1 expression in predicting PSA recurrence
in stage pT2 prostate cancers treated by radical prosta-
tectomy alone.
Methods
Between January 1991 and December 2003, a total
of 275 patients underwent radical prostatectomy in
our institute for clinically localized prostate cancers.
Among them, 153 (55.6%) were pT2 disease. Medical
records were reviewed, and patients who had neo-
adjuvant or adjuvant therapy were excluded. To avoid
the possibility of understaging, only patients with
postoperative PSA < 0.01 ng/mL on the PSA-RIACT
(CIS Bio International, Cedex, France) assay were
enrolled.
All patients were advised to have PSA follow-up
every 3 months in the first year after operation and 
at least biannually thereafter. Biochemical relapse was
defined as 2 consecutive PSA measurements > 0.2 ng/
mL with an interval of more than 3 months. PSA pro-
gression-free survival time was defined as the time from
radical prostatectomy to the first follow-up date showing
PSA > 0.2 ng/mL or until the last follow-up.
All original pathologic slides were reviewed by 
1 pathologist (JSW) to reassign the Gleason scores
and pathologic stage. The 1997 AJCC TNM staging
system was used. A representative section containing
the poorest tumor grade in the radical prostatectomy
specimen was selected for immunohistochemical study.
Serial 4 μm sections from corresponding archival
blocks were dewaxed, rehydrated, and microwave heat
retrieved. Sections were incubated with anti-p21WAF1
(SX118) and anti-p27KIP1 (SX53G8) antibodies (Dako-
Cytomation, Denmark) according to manufacturer
recommendations.
Two investigators (JSW and TTLW) examined all
immunostained sections while blinded to the clinical
data. Any amount of tumor nuclei demonstrating
p21WAF1 immunoreactivity was categorized as posi-
tive.11 p27KIP1 nuclear staining was assessed on a 
continuous scale from 0% to 100% by estimating a 
positive-to-total ratio. Different cutoffs have been
recommended.17,18 Based on the study of Vis et al,18
an optimal cutoff point of 25% (for pT2 disease) was
selected for statistical analysis.
Statistical analysis was performed using SPSS version
10.0 (SPSS Inc., Chicago, IL, USA). Association be-
tween Gleason score on radical prostatectomy specimens
with p21WAF1 and p27KIP1 expression was calculated
using Fisher’s exact test. Kaplan-Meier survival curves
and the log-rank test were used to assess the prognos-
tic significance of p21WAF1 and p27KIP1 in predicting
biochemical failure. All reported p values were 2-sided,
and p < 0.05 was considered statistically significant.
Results
A total of 53 patients were enrolled; their basic demo-
graphic data are listed in Table 1. At a median follow-up
of 49 months (range, 10–117 months), 15 patients
(28.3%) experienced biochemical recurrence. The 
5- and 10-year PSA progression-free probabilities
were 69% and 62.7%, respectively.
We identified p21WAF1 immunoreactivity in 19
patients (35.8%). Twenty-nine tumors (54.7%) had
decreased p27KIP1 expression (Figure 1). No association
of these immunohistochemical markers with Gleason
score was identified (p = 1.000 for both; Table 2).
Kaplan-Meier survival analysis and log-rank test dis-
closed no association of p21WAF1 or p27KIP1 expression
with PSA progression-free survival (p = 0.988 and
p = 0.641, respectively; Figure 2). Among 15 patients
who experienced biochemical failure, 5 (33.3%) 
overexpressed p21WAF1 and 7 (46.7%) had decreased
p27KIP1 expression (p = 1.000 and p = 0.54, respectively,
Pearson’s χ2 test).
Table 1. Patient characteristics
Median age, yr (range) 70 (57–75)
Initial prostate specific antigen
Median, ng/mL (range) 10.0 (2.4–52.8)
≤ 4.0, n (%) 2 (3.8)
4.1–10.0, n (%) 25 (47.2)
10.1–20.0, n (%) 17 (32.1)
> 20.0, n (%) 9 (17)
Surgical Gleason score
Median (range) 6 (2–9)
2–6, n (%) 43 (81.1)
7, n (%) 8 (15.1)
9, n (%) 2 (3.8)
Pathologic stage, n (%)
T2a 17 (32.1)
T2b 36 (67.9)
Discussion
With the wide application of PSA tests, most of the
prostate cancers diagnosed today are clinically localized
diseases and have a good probability of being cured by
radical prostatectomy. Preoperative PSA, Gleason score
and tumor stage are well established prognostic indica-
tors for prostate cancer.2 However, there remains signif-
icant variation in individual patient outcome when
these traditional markers are applied.11,18 To improve
predictive accuracy, many molecular markers are under
investigation.18
p21WAF1 is a product of the WAF1 gene that plays
an essential role in the initiation of G1 arrest in res-
ponse to DNA damage.4–9,22 As a product of the tumor
suppressor gene, p21WAF1 should have lower expression
in aggressive tumors.11 However, Adsay et al illustrated
a significant correlation between p21WAF1 expression
and advanced stage, but only a trend for higher Gleason
score.10 In the present study, we did not observe a
correlation between p21WAF1 expression and Gleason
score. As to its prognostic significance, Byrne et al
identified no relationship between p21WAF1 expression
and patient outcome.23 On the contrary, Lacombe et al
found p21WAF1 overexpression to be an independent
predictor for PSA failure in pT3 patients after radical
prostatectomy.13 In the study of Aaltomaa et al, p21WAF1
expression indicated poorer outcome only in clinically
localized prostate cancers but not metastatic disease.12
Interestingly, Sarkar et al found that p21WAF1 served as
a prognostic marker for Caucasians but not for African-
Americans.11 Our study also found that p21WAF1 had
no prognostic significance for organ-confined prostate
cancers.
The frequency of loss of p27KIP1 expression in our
patients (54.2% and 62.7% at cutoffs of 25% and 50%,
respectively) was much higher than that reported by
Yang et al (16.3% at cutoff of 30%)17 and Vis et al (38%
at cutoff of 50%).18 Decreased p27KIP1 expression has
recently been reported to be associated with higher
tumor grade.19,21 Consistent with the findings of
Kuczyk et al,3 we could not correlate p27KIP1 expression
with Gleason scores. Some investigators reported that
low expression of p27KIP1 is an independent predictor
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Figure 1. (A) Negative stain for p21; (B) positive nuclear stain for p21; (C) negative stain for p27 (stain of cytoplasm only); (D) strong
positive nuclear stain for p27. (Magnification: all 200×.)
Table 2. Association between Gleason scores and p21 and p27
expression (Pearson’s χ2 test)
p21 p27
Negative Positive Negative Positive
Gleason score
≤ 6 28 (65%) 15 (35%) 24 (56%) 19 (44%)
≥ 7 6 (60%) 4 (40%) 5 (50%) 5 (50%)
p 1.000 1.000
for biochemical failure and disease-specific survival in
prostate cancers,3,17,18,20,21 while some could not
confirm this correlation.24 We also failed to establish
p27KIP1 expression as a prognostic indicator for organ-
confined prostate cancers. However, the unusually high
frequency of loss of p27KIP1 expression in Taiwanese
prostate cancer patients might at least partially explain
why our patients had a higher incidence of biochemical
recurrence compared to Caucasians.
To improve the outcome of management of pros-
tate cancer, identifying individuals at risk of disease
recurrence after radical prostatectomy is very important,
especially in the subset of patients with organ-confined
tumors. Previously, we found that overexpression of
bcl-2 and aberrant expression of E-cadherin are adverse
prognostic factors.14 In the current study, we failed to
find any association of p21WAF1 or p27KIP1 with PSA
progression-free survival in patients with localized pros-
tate cancers. The main limitations of the present study
were the small sample size and short follow-up period.
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Figure 2. Kaplan-Meier survival curves with log-rank test p value: (A) p21; (B) p27. PSA = prostate specific antigen.
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